Description
Global Neuropathic Pain Market Research Report – Forecast to 2027
Market analysis
Neuropathic Pain Market is anticipated to surpass USD 28,778.20 million by 2027 at a notable CAGR of 6.3% during the review period.
Neuropathic pain is prominently caused by the peripheral nerve disorder. The global market growth is attributed to the introduction of pain management centers along with higher demand for generic drugs.
In Neuropathic Pain Market, diabetes is one of the main sources of expanded neuropathic torment. The subsequent primary driver of neuropathic torment is the destructive infection called disease. According to World Health Organization (WHO) reports, in 2014, there were around 422 million individuals who were experiencing diabetes.
The huge populace is likewise viewed as one of the essential basic drivers of the market. Likewise, better treatment offices, improvement of medical care frameworks, ascend popularity of neuropathic torment and critical ventures by pharma organizations, improvement in nature of medications, and quantities of torment the board frameworks will push the market on a positive course.
Market segmentation
Based on type segment, the global neuropathic pain market has been classified into peripheral neuropathy, post-traumatic neuropathy, post-herpetic neuralgia (PHN), phantom limb pain, entrapment neuropathy, and trigeminal neuralgia. Based on indication, the market is divided into chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and spinal stenosis. In terms of diagnosis, the market is segmented into blood tests, imaging, and physical examination. Based on its treatment, the market is classified into medication type and multimodal therapy. The end-use industries include clinics, hospitals, and research organizations. Based on its distribution channels, the market is divided into online pharmacies and retail pharmacies & drug stores.
Regional analysis
The nations in North America and South America contained an all-out market esteem worth of USD 6,645.09 million in the year 2019. It is anticipated that it will arrive at a CAGR of around 5.6% during the gauge time frame. The rising number of problems connected with neuropathic torment, mechanical turns of events, and ascend in mindfulness are the fundamental elements of the Neuropathic Pain Market development.
The American market is grouped into North America and Latin America. The market of North America is additionally partitioned into the United States of America and Canada.
The neuropathic torment market in Western Europe has been isolated into France, the UK, Germany, Spain, Italy, and other European nations. The market in Asia-Pacific is sectioned into India, Japan, Australia, China, South Korea, and different nations in the Asia-Pacific area. The Market in the Middle East and African district is separated into the Middle East and Africa.
Major players
Sanofi S.A. (France), Abbott Laboratories (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Tokyo), Biogen Inc. (U.S.), Baxter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.), among others, are some of the major players in the global neuropathic pain market.
Table of Contents
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION 22
2.2 SCOPE OF THE STUDY 22
2.3 RESEARCH OBJECTIVE 22
2.4 MARKET STRUCTURE 23
2.5 ASSUMPTIONS & LIMITATIONS 24
3 RESEARCH METHODOLOGY
3.1 DATA MINING 25
3.2 SECONDARY RESEARCH 26
3.3 PRIMARY RESEARCH 27
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 28
3.5 FORECASTING TECHNIQUES 29
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 30
3.6.1 BOTTOM-UP APPROACH 31
3.6.2 TOP-DOWN APPROACH 31
3.7 DATA TRIANGULATION 32
3.8 VALIDATION 32
4 MARKET DYNAMICS
4.1 OVERVIEW 33
4.2 DRIVERS 34
4.2.1 RISING PREVALENCE OF DIABETIC NEUROPATHY 34
4.2.2 INCREASING HEALTHCARE EXPENDITURE 34
4.2.3 GROWING NUMBER OF INCIDENCE OF TRAUMA FROM INJURY AND OTHER CONDITIONS 35
4.3 RESTRAINTS 36
4.3.1 INCREASING COUNTERFEIT DRUGS & SIDE EFFECTS OF THE THERAPEUTIC TREATMENT 36
4.3.2 LACK OF AWARENESS ABOUT THE NEUROLOGICAL CONDITION 37
4.4 OPPORTUNITIES 38
4.4.1 NEW PRODUCT LAUNCH IN DEVELOPING REGIONS 38
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 39
5.1.1 R&D 40
5.1.2 MANUFACTURING 40
5.1.3 DISTRIBUTION AND SALES 40
5.1.4 POST-SALES MONITORING 40
5.2 PORTER’S FIVE FORCES MODEL 41
5.2.1 BARGAINING POWER OF SUPPLIERS 42
5.2.2 BARGAINING POWER OF BUYERS 42
5.2.3 THREAT OF NEW ENTRANTS 42
5.2.4 THREAT OF SUBSTITUTES 42
5.2.5 INTENSITY OF RIVALRY 42
5.3 IMPACT ANALYSIS OF COVID-19 ON THE GLOBAL NEUROPATHIC PAIN MARKET 43
5.3.1 OVERVIEW 43
5.3.2 IMPACT ON ONGOING TREATMENTS AND DELAYED AVAILABILITY DUE TO DEFERMENT 43
5.3.3 IMPACT ON NUMBER OF PATIENTS 44
6 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE
6.1 OVERVIEW 45
6.2 PERIPHERAL NEUROPATHY 47
6.3 ENTRAPMENT NEUROPATHY 47
6.4 TRIGEMINAL NEURALGIA 48
6.5 PHANTOM LIMB PAIN 48
6.6 POST HERPETIC NEURALGIA (PHN) 49
6.7 POST TRAUMATIC NEUROPATHY 49
7 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION
7.1 OVERVIEW 50
7.2 DIABETIC NEUROPATHY 52
7.3 SPINAL STENOSIS 52
7.4 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY 53
7.5 OTHERS 53
8 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS
8.1 OVERVIEW 54
8.2 IMAGING 55
8.3 BLOOD TESTS 56
8.4 PHYSICAL EXAMINATION 56
9 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT
9.1 OVERVIEW 57
9.2 MEDICATION 58
9.3 MULTIMODAL THERAPY 60
10 GLOBAL NEUROPATHIC PAIN SMARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW 61
10.2 RETAIL PHARMACIES & DRUG STORES 62
10.3 ONLINE PHARMACIES 62
11 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER
11.1 OVERVIEW 63
11.2 HOSPITALS 64
11.3 CLINICS 64
11.4 RESEARCH ORGANIZATIONS 65
12 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION
12.1 OVERVIEW 66
12.2 AMERICAS 67
12.2.1 NORTH AMERICA 72
12.2.1.1 US 77
12.2.1.2 CANADA 81
12.2.2 LATIN AMERICA 85
12.3 EUROPE 90
12.3.1 WESTERN EUROPE 95
12.3.1.1 GERMANY 100
12.3.1.2 UK 104
12.3.1.3 FRANCE 108
12.3.1.4 ITALY 112
12.3.1.5 SPAIN 116
12.3.1.6 REST OF WESTERN EUROPE 120
12.3.2 EASTERN EUROPE 124
12.4 ASIA-PACIFIC 129
12.4.1 CHINA 134
12.4.2 INDIA 138
12.4.3 JAPAN 142
12.4.4 SOUTH KOREA 146
12.4.5 AUSTRALIA 150
12.4.6 REST OF ASIA-PACIFIC 154
12.5 MIDDLE EAST & AFRICA 159
12.5.1 MIDDLE EAST 164
12.5.2 AFRICA 168
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW 173
13.2 COMPETITIVE BENCHMARKING 174
13.3 GLOBAL NEUROPATHIC PAIN MARKET: COMPANY RANKING, 2020 175
13.4 MAJOR GROWTH STRATEGY IN THE GLOBAL NEUROPATHIC PAIN MARKET 175
13.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 176
13.6 COMPETITIVE BENCHMARKING: GLOBAL NEUROPATHIC PAIN MARKET 176
13.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 177
13.7.1 PRODUCT APPROVALS AND LAUNCHES 177
13.7.2 ACQUISITIONS 177
13.8 FINANCIAL MATRIX 178
14 COMPANY PROFILES
14.1 ABBOTT 179
14.1.1 COMPANY OVERVIEW 179
14.1.2 FINANCIAL OVERVIEW 180
14.1.3 PRODUCTS/SERVICES OFFERED 180
14.1.4 KEY DEVELOPMENTS 181
14.1.5 SWOT ANALYSIS 182
14.1.6 KEY STRATEGIES 182
14.2 PFIZER 183
14.2.1 COMPANY OVERVIEW 183
14.2.2 FINANCIAL OVERVIEW 183
14.2.3 PRODUCTS/SERVICES OFFERED 184
14.2.4 KEY DEVELOPMENTS 184
14.2.5 SWOT ANALYSIS 184
14.2.6 KEY STRATEGIES 184
14.3 JOHNSON & JOHNSON SERVICES, INC. 185
14.3.1 COMPANY OVERVIEW 185
14.3.2 FINANCIAL OVERVIEW 186
14.3.3 PRODUCTS/SERVICES OFFERED 186
14.3.4 KEY DEVELOPMENTS 186
14.3.5 SWOT ANALYSIS 187
14.3.6 KEY STRATEGIES 187
14.4 BAXTER INTERNATIONAL 188
14.4.1 COMPANY OVERVIEW 188
14.4.2 FINANCIAL OVERVIEW 188
14.4.3 PRODUCTS/SERVICES OFFERED 189
14.4.4 KEY DEVELOPMENTS 189
14.4.5 SWOT ANALYSIS 189
14.4.6 KEY STRATEGIES 190
14.5 ELI LILY AND COMPANY 190
14.5.1 COMPANY OVERVIEW 190
14.5.2 FINANCIAL OVERVIEW 191
14.5.3 PRODUCTS/SERVICES OFFERED 191
14.5.4 KEY DEVELOPMENTS 191
14.5.5 SWOT ANALYSIS 192
14.5.6 KEY STRATEGIES 192
14.6 GLAXOSMITHKLINE PLC 193
14.6.1 COMPANY OVERVIEW 193
14.6.2 FINANCIAL OVERVIEW 193
14.6.3 PRODUCTS/SERVICES OFFERED 194
14.6.4 KEY DEVELOPMENTS 194
14.6.5 SWOT ANALYSIS 194
14.6.6 KEY STRATEGIES 195
14.7 SANOFI 195
14.7.1 COMPANY OVERVIEW 195
14.7.2 FINANCIAL OVERVIEW 196
14.7.3 PRODUCTS/SERVICES OFFERED 196
14.7.4 KEY DEVELOPMENTS 197
14.7.5 SWOT ANALYSIS 197
14.7.6 KEY STRATEGIES 197
14.8 ASTRAZENECA 198
14.8.1 COMPANY OVERVIEW 198
14.8.2 FINANCIAL OVERVIEW 198
14.8.3 PRODUCTS/SERVICES OFFERED 199
14.8.4 KEY DEVELOPMENTS 199
14.8.5 SWOT ANALYSIS 199
14.8.6 KEY STRATEGIES 199
14.9 DEPOMED INC. (ASSERTIO THERAPEUTICS, INC) 200
14.9.1 COMPANY OVERVIEW 200
14.9.2 FINANCIAL OVERVIEW 200
14.9.3 PRODUCTS/SERVICES OFFERED 200
14.9.4 KEY DEVELOPMENTS 201
14.9.5 SWOT ANALYSIS 201
14.9.6 KEY STRATEGIES 202
14.10 BIOGEN, INC. 202
14.10.1 COMPANY OVERVIEW 202
14.10.2 FINANCIAL OVERVIEW 202
14.10.3 PRODUCTS/SERVICES OFFERED 203
14.10.4 KEY DEVELOPMENTS 203
14.10.5 SWOT ANALYSIS 203
14.10.6 KEY STRATEGIES 203
14.11 ASTELLAS PHARMA LTD. 204
14.11.1 COMPANY OVERVIEW 204
14.11.2 FINANCIAL OVERVIEW 204
14.11.3 PRODUCTS/SERVICES OFFERED 205
14.11.4 KEY DEVELOPMENTS 205
14.11.5 SWOT ANALYSIS 205
14.11.6 KEY STRATEGIES 206
15 APPENDIX
15.1 REFERENCES 207
15.2 RELATED REPORTS 207
Reviews
There are no reviews yet.